When tumors were stratified by mutation and tumor type, the means of these three scores (HRD-Mean) were significantly higher in BRCA1 and BRCA2 germline mutation-associated breast vs. nonBRCA breast tumors, and between BRCA1 germline mutation-associated and nonBRCA ovarian tumors (Supplementary Fig. 3d). This evidence concerns the gene BRCA1 and breast neoplasm.